N/A N=595 Surveillance of Kaletra in Korean Patients
HIV-1 Infection
Primary: Number of Participants With Adverse Events — 363; 285 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=31 Sugammadex ED90 Dose in the Obese Patients
Incomplete Reversal of Neuromuscular Block
Primary: Sugammadex ED90 — 2.40 mg/kg
Phase 2 N=6 The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Pulmonary Hypertension · Pulmonary Arterial Hypertension
Primary: Pain Score on a Visual Analogue Scale — 2.89 Visual Analogue Scale — p=0.03
Phase 4 N=197 A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Envelope Antigen Seroconversion at Week 48 — 14.89; 6.12 Percentage of participants
Phase 2 N=25 High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
N/A N=100 Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates
Polyps
Primary: Number of Adenomas — 83; 89; 28; 44 First Colonoscopy number of adenomas
N/A N=220 An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
Breast Cancer
Primary: Median Overall Survival — 2.51 Years
N/A N=27 Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Auditory Hallucinations
Primary: Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5 — -6.38; -8.54 units on a scale — p=0.48
Phase 3 N=503 Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Post-Stroke Cognitive Impairment (PSCI)
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale + Cognitive Subscale Extended Version (ADAS-cog+) at Month 6 — -6.8; -4.6 score on a scale — p=0.005
Phase 4 N=90 A Trial Of Oral Chloral Hydrate Versus Intranasal Dexmedetomidine For Sedated Abr Exams
Sedation
Primary: Time to Complete Study — 85.5; 110 Minutes
Phase 3 N=376 AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression Free Survival During Maintenance Treatment Phase — 6.6; 10.2 Months — p=<0.001
N/A N=30 Visualization of the Larynx With the Airtraq Laryngoscope and Image Transmission
Anaesthesia
Primary: Visualization of Larynx With the Airtraq Laryngoscope and Handphone — 30 participants
Phase 3 N=28 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
Hypervascular Tumor and Arteriovenous Malformation
Primary: Success Rate of Embolization in the Target Vessel — 100; 96.4 Percentage of participants
Phase 4 N=8 Short Bowel Syndrome and Teduglutide Versus Placebo
Short Bowel Syndrome
Primary: Gastric Emptying Half-Time (T1/2) — 113; 106 minutes — p=0.74
N/A N=154 MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Primary: Probability of Event Free Survival (EFS) — 0.695 probability of EFS